23 98

Cited 0 times in

Feasibility of allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan in patients relapsed after autologous hematopoietic stem cell transplantation

Other Titles
 자가 조혈모세포이식 이후 재발한 환자에서의 fludarabine과 melphan을 사용한 저강도 전처치 동종 조혈모세포이식 
Authors
 홍정용 
Issue Date
2011
Description
Dept. of Medicine/석사
Abstract
The current study was performed to determine the feasibility of allogeneic hematopoietic stem cell transplantation (HSCT) using reduced-intensity conditioning (RIC) with fludarabine and melphalan in patients relapsed after autologous HSCT. Twelve patients (multiple myeloma n=7, non-Hodgkin’s lymphoma n=3, acute myeloid leukemia n=2) received allogeneic HSCT using the RIC with fludarabine (25mg/m2 for 5days) and melphalan (140mg/m2 for 1day) for relapsed disease after a prior autologous HSCT. The graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine plus a mini-dose of methotrexate. All patients achieved a neutrophil or platelet engraftment in a median of 13.5 days and 17.5 days, respectively. The transplant-related mortality was 2 patients (16.7%). Grade II~IV acute GVHD and chronic extensive GVHD was noted in 4 (33.3%) and 1 patient (11.1%), respectively. Over a median follow-up duration of 12.5 months, 5 patients are currently alive without evidence of disease. The estimated non-relapse mortality (NRM) at 1 year was 28.4%. The estimated overall survival (OS) rate at 1 year 2was 58.3% and the estimated event-free survival (EFS) rate at 1 year was 41.7%. Allogeneic HSCT using RIC with fludarabine and melphalan appears to be feasible for a second HSCT in patients relapsed after autologous HSCT.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/134142
Appears in Collections:
2. Thesis / Dissertation (학위논문) > 1. College of Medicine (의과대학) > Master's Degree (석사)
사서에게 알리기
  feedback
Files in This Item:
T012384.pdf Download
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse